Monday, 23 April 2018 - 10:42
  • it
  • de
  • en
  • fr


Pfizer: FDA approves Lyrica CR

Pfizer has announced that FDA has approved Lyrica CR (pregabalin) extended-release tablets as once-daily therapy for the management of neuropathic pain associated with diabetic neuropathy and the management of postherpetic neuralgia. The drug has not received approval for the management…

Pfizer’s Lyrica in pediatric epilepsy, positive Phase III results

Pfizer today announced positive results from a Phase-III clinical trial aimed at evaluating the use of Lyrica (pregabalin) capsules and oral solution as adjunctive therapy for pediatric epilepsy in patients between 4 and 16 years of age. Adjunctive treatment with…